|
Agents | Study type | Dose | Time | Outcomes | Ref. |
|
Rosiglitazone | Randomized placebo-controlled (FLIRT) Trial | 4 mg/day 1 month and after 8 mg/day | 1 year and 4 months | Improvement of steatosis correlated with reduction of transaminase level improvement in insulin sensitivity. | [163] |
Randomized placebo-controlled (FLIRT 2) extension trial | 4 mg/day 1 month and after 8 mg/day | 3 years | Improvement in ALT and liver steatosis but no results on ballooning and fibrosis. | [164] |
Pioglitazone | Randomized, double-blind, placebo-controlled trial | 30 mg/day | 2 years | Improvement in individual histologic scores, adipose tissue, hepatic, and muscle insulin sensitivity. | [166] |
Pioglitazone vs. ipragliflozin | Open-label, randomized, active-controlled trial | 15-30 mg/day vs. 50 mg/day | 6 months | AST and ALT, HbA1c, and fasting plasma glucose were similarly reduced in the two-treatment group. | [169] |
Liraglutide | Randomised, placebo-controlled phase 2 study (LEAN) study | 1.8 mg/day | 1 year | Improvements in histological steatosis and hepatocyte ballooning. | [172] |
Double-blind, randomised, placebo-controlled trial | 1.8 mg/day | 3 months | Reduced BMI, DNL, IR, and hepatic steatosis. | [173] |
Open-label, active-controlled parallel-group, multicentre trial | 3 mg/day | 6 months | Reduced BMI, hepatic steatosis, and hepatocellular apoptosis. | [176] |
Prospective, single-center study (LEAN-J). | 1.2 mg/day | 2 years | 31% reduction of hepatic steatosis | [179] |
Canagliflozin | A prospective study | 100 mg/day | 6 months | Improvement in histopathologic features and markers of liver dysfunction | [183] |
A prospective study | 100 mg/day | 6 months | Histological improvement, improvement of IR. | [184] |
Prospective study | 100 mg/day | 6 months | Improvement in ALT and liver steatosis | [186] |
Empagliflozin | Randomised controlled trials (E-LIFT Trial) | 10 mg/day | 5 months | Improvement in liver steatosis and serum ALT level. | [187] |
Single-arm, open-label, pilot study | 25 mg/day | 6 months | Reduction in BMI, cholesterol, GGT, ballooning, and fibrosis. | [188] |
Dapagliflozin | Randomised controlled trial | 10 mg/day | 4 months | Reduction in BMI, AST, ALT, and liver steatosis. | [189] |
An open-label, randomized trial | 5 mg/day | 6 months | Improvements in hepatic steatosis, along with attenuation of fibrosis in a subset of patients with significant fibrosis. | [190] |
Luseogliflozin | A prospective, single-arm trial (LEAD trial) | 2.5 mg/day | 6 months | Improvement of steatosis correlated with reduction of transaminase level | [195] |
|